CNS
Central Nervous System Market Research CNS), Intelligence and Forescasts
In this section you will find information products, including market research, covering Central Nervous System research, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
|
The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
December 2009 | £2310 |
|
CNS Therapeutics A World Market Review |
November 2009 | £1980 |
|
The Global Multiple Sclerosis Market 2009-2024 |
March 2009 | £1499 |
|
Neurodegenerative Market Forecast to 2013 |
February 2009 | £6600 |
|
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders |
December 2008 | £2475 |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £5285 |
|
MarketWatch: CNS |
November 2008 | £69 |
|
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail |
November 2008 | £2640 |
|
The CNS Market Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
September 2008 | £1995 |
|
CNS Generic Drugs: Prospects and Opportunities to 2012 |
April 2008 | £995 |
|
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors |
April 2008 | £5285 |
|
Pharmacological and Psychosocial Treatments in Schizophrenia |
January 2008 | £35.95 |
|
Pipeline Insight Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
November 2007 | £1980 |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £5020 |
|
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits |
September 2007 | £5020 |
|
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack |
September 2007 | £5020 |
|
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market |
September 2007 | £395 |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 |
|
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
June 2007 | £995 |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £3965 |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 |
|
Stakeholder Insight: Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice |
December 2006 | £5285 |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £5285 |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £3965 |
|
CNS Drug Discoveries: Multiple Sclerosis |
November 2006 | £795 |
|
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD) |
November 2006 | £795 |
|
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
November 2006 | £3965 |
|
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
October 2006 | £3965 |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £4290 |
|
Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area |
December 2005 | £795 |
|
Neuroscience Perspective; The Opportunities for Market Entry & Expansion |
October 2005 | £2970 |
